Filing Details
- Accession Number:
- 0001209191-22-027646
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-06 17:07:23
- Reporting Period:
- 2022-04-14
- Accepted Time:
- 2022-05-06 17:07:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1087294 | Cumberland Pharmaceuticals Inc | CPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1632384 | C Joseph Galante | 2525 West End Avenue Suite 950 Nashville TN 37203 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-04-14 | 56 | $2.71 | 45,117 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-18 | 56 | $2.63 | 45,173 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-19 | 56 | $2.69 | 45,229 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-20 | 56 | $2.74 | 45,285 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-21 | 56 | $2.75 | 45,341 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-22 | 56 | $2.73 | 45,397 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-25 | 61 | $2.62 | 45,458 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-26 | 61 | $2.53 | 45,519 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-27 | 61 | $2.41 | 45,580 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-28 | 61 | $2.51 | 45,641 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-04-29 | 61 | $2.44 | 45,702 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.